<DOC>
	<DOCNO>NCT01409603</DOCNO>
	<brief_summary>The primary objective study evaluate whether naproxen darexaban different effect blood coagulation influence effect . Also investigate whether blood level either drug influence presence drug . In addition , safety tolerability drug combination drug investigate .</brief_summary>
	<brief_title>To Evaluate Whether Naproxen Darexaban ( YM150 ) Interact Their Effects</brief_title>
	<detailed_description />
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Body mass index ( BMI ) 18.530.0 kg/m2 Male subject must nonfertile , i.e . surgically sterilize must practice adequate contraceptive method prevent pregnancy Known suspect hypersensitivity darexaban naproxen component formulation use A contraindication use naproxen Any liver function test ( i.e . ALT , AST bilirubin ) upper limit normal repeated measure Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic judge medical investigator . Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG clinical laboratory test Use prescribed OTC ( overthecounter ) drug ( include vitamin , natural herbal remedy , e.g . St. John 's wort ) 2 week prior admission Clinical Unit , except occasional use paracetamol ( 3 g/day ) Regular use inducer liver metabolism ( e.g . barbiturate , rifampicin ) 3 month prior admission Clinical Unit Donation blood blood product within 3 month prior admission Clinical Unit Any use drug abuse , smoke 10 cigarette ( equivalent ) 21 unit ( 210 g ) alcohol per week within 3 month prior study Participation clinical study within 3 month participation 3 clinical study within 12 month , prior expect date enrolment study , provide clinical study entail biological compound long terminal half life</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Pharmacodynamics</keyword>
	<keyword>darexaban</keyword>
	<keyword>naproxen</keyword>
	<keyword>YM150</keyword>
	<keyword>Phase 1</keyword>
</DOC>